University of Pittsburgh Cancer Institute
Develop and validate nuclear matrix proteins as biomarkers for early detection of colon cancer.
An integrated multi-disciplinary approach will be used to identify biomarkers for colorectal cancer. The team includes basic cancer researchers and clinicians supported by faculty with expertise in biostatistics/bioinformatics.
- Characterize, evaluate, and validate a set of unique nuclear matrix proteins (NMPs) which are expressed in colorectal cancer.
- Undertake an extensive Phase 1 and 2 validation study to assess the performance of the NMP biomarker, CC2, for serum-based early detection of colorectal cancer.
- Characterize and evaluate other NMPs, with varying spectrums of expression in pre-malignant (adenomas) and malignant tissue, as potential biomarkers of early disease and/or risk.
University Of Pittsburgh Cancer Institute
> 305 Iroquois Bldg.<br> 200 Lothrop St.
> Pittsburgh, PA 15213<br> Tel: (412) 967-6534
> Fax: (412) 967-6576<br> Email: email@example.com